BAFNA PHARMACEUTICALS
|
|
BOM : 532989     NSE : BAFNAPH     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : NA |
May 27,2022 |
Price(EOD): ₹ 122.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 289.61 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
BAFNA PHARMACEUTICALS | -5.3% | -7.6% | -14.4% |
SUN PHARMACEUTICAL INDUSTRIES | -1.9% | -0.2% | 29.4% |
DIVIS LABORATORIES | -9.8% | -22.2% | -15.5% |
DR REDDYS LABORATORIES | 2.8% | 7.7% | -17.4% |
CIPLA | -0.4% | -1.1% | 3.1% |
GLAND PHARMA | -2.5% | -7.7% | -13% |
PIRAMAL ENTERPRISES | -12.8% | -23.8% | 9.1% |
CADILA HEALTHCARE | 3.1% | 8.4% | -40.1% |
TORRENT PHARMACEUTICALS | 12.4% | 8.5% | 6.5% |
FUNDAMENTAL ANALYSIS OF BAFNA PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF BAFNA PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
-
P/E Calculated based on EPS of -9.17
[ Mar2020 - Consolidated Results ] -
P/B Calculated based on Book Value of -17.93
[ Mar2020 - Consolidated Results ] 6.82
P/S Calculated based on Revenues of 42.472 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA 316% 805% |
SHARE PRICE MOMENTUM OF BAFNA PHARMACEUTICALS
BAFNA PHARMACEUTICALS vs SENSEX
DEBT OF BAFNA PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.27 -0.68 2.22 0.6 |
- -0.71 2.43 0.57 |
[Last Annual Data : Mar2020]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF BAFNA PHARMACEUTICALS
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF BAFNA PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
20.21% 1820.81% 109.76% 102.71% |
0.44% 262.2% 1781.9% 860.32% |
QtrlyTrend |
8 | |
Latest Qtr: Mar2020 | ||
Quarterly Result Analysis → |
BAFNA PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about BAFNA PHARMACEUTICALS
Is BAFNA PHARMACEUTICALS good for long term investment?
As on May 27,2022, the Fundamentals of BAFNA PHARMACEUTICALS look Poor and hence it may not be good for long term investment ! See Financial Performance of BAFNA PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is BAFNA PHARMACEUTICALS UnderValued or OverValued?
As on May 27,2022, BAFNA PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of BAFNA PHARMACEUTICALS ?
As on May 27,2022, the Intrinsic Value of BAFNA PHARMACEUTICALS is Rs. 21.44 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -113.72
Fair Value [Median EV / Sales Model] : Rs. 29.38
Fair Value [Median Price / Sales Model] : Rs. 13.50
Median Fair Value of BAFNA PHARMACEUTICALS : Rs. 21.44
Is BAFNA PHARMACEUTICALS trading at a Premium or Discount?
As on May 27,2022, BAFNA PHARMACEUTICALS is trading at a Premium of 470% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
